Latest News From Open Orphan!
Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce the signing of a new 3-year contract with a tier 1 German pharmaceutical company which is one of Europe’s top research-driven pharmaceutical companies. The company released the RNS on 6/1/20 in which the CEO Cathal Friel commented: ” by transitioning from ad-hoc short-term contracts to long-term contracts with high-quality customers thereby delivering secured recurring revenues for the business “ much of the speculation was around the contract with German Tier 1 partner rumoured to be Boehringer Ingelheim
On Tuesday Open Orphan announced it had received over 90 percent, acceptances of the hVIVO Shares to which the Offer relates, Open Orphan intends, subject to the Offer becoming unconditional in all respects, to now exercise its rights pursuant to the provisions of sections 974-991 of the Companies Act to compulsorily acquire the remaining hVIVO Shares concluded the second major transaction in quick succession from Open Orphan.
You can hear more from Chairman Cathal Friel by clicking the play bar below
Executive Chairman Cathal Friel recently spoke to our friends at proactive here
The author was remunerated but does not hold shares in the company